Article Text

Download PDFPDF

LB-015 Multicenter early us feasibility study & periprocedural safety of LVIS EVO for the treatment of unruptured intracranial aneurysms
Free
  1. Y Kayan1,
  2. J Delgado Almandoz1,
  3. A Copelan2,
  4. I Chaudry3,
  5. C Matouk4,
  6. D Altschul5,
  7. M Amir Essibayi5,
  8. O Goren6,
  9. B Yim7,
  10. S Tsappidi8,
  11. Y Zhang8,
  12. F Hui9,
  13. E Samaniego10,
  14. A Gudino10,
  15. A Siddiqui11,
  16. V Jaikumar11,
  17. A Puri12,
  18. A Kuhn13,
  19. J Singh13,
  20. A Ringer14,
  21. R Hanel15,
  22. O De Toledo16,
  23. G Dabus17,
  24. M Gooch18,
  25. S Sizdahkhani18,
  26. N Field19,
  27. A Custozzo19,
  28. A Paul19
  1. 1Department of Radiology, Abbott Northwestern Hospital, Minneapolis, MN
  2. 2Abbott Northwestern Hospital, Minneapolis, MN
  3. 3Prisma Health, Greenvile, SC
  4. 4Yale University, New Haven, CT
  5. 5Montefiore Medical Center, Bronx, NY
  6. 6Geisinger Health System, Danville, PA
  7. 7John Muir Health, Walnut Creek, CA
  8. 8The Queen’s Health System, Honolulu, HI
  9. 9The Queen’s Health Center, Honolulu, HI
  10. 10University of Iowa, Iowa City, IA
  11. 11Jacobs School of Medicine, Buffalo, NY
  12. 12Albany Medical Center, Worcester, MA
  13. 13University of Massachussetts, Worcester, MA
  14. 14Mayfield Brain and Spine, Cincinnati, OH
  15. 15Baptist Health, Jacksonville, FL
  16. 16Bapist Health, Jacksonville, FL
  17. 17Baptist Health South Florida, Miami, FL
  18. 18Thomas Jefferson University, Philadelphia, PA
  19. 19Albany Medical Center, Albany, NY

Abstract

Background The LVIS EVO is the second generation version of the Low-Profile Visualized Intraluminal Support(LVIS) with improved visibility and resheathability and underwent a limited premarket release(PMR) in December 2023. This study aims to report the early safety and feasibility experience with the LVIS EVO stent for the treatment of intracranial aneurysms in the United States.

Methods This is a multicenter retrospective observational study evaluating patients who underwent treatment of an intracranial aneurysm with an LVIS EVO stent after the limited PMR. Any patient 18 years or older who underwent treatment of an intracranial aneurysm with a LVIS EVO stent in the United States was included from the initial PMR in December 2023 until April 2024. Patient age(or ≤90 years old), sex, preoperative mRS, aneurysm location, aneurysm measurements, and information about preoperative antiplatelet management were all collected. Data on periprocedural complications, 30-day mortality, discharge mRS and length of stay were also collected.

Results 53 patients with 55 aneurysms underwent treatment with the LVIS EVO stent at 15 institutions. All aneurysms were unruptured. The most common location was the anterior communicating artery(35%) followed by the middle cerebral artery bifurcation(31%). All patients were on dual antiplatelet therapy. The average aneurysm size was 5.2mm with a neck size of 3.7 mm. The smallest distal parent vessel size was 1.2 mm and 36% of stents were deployed in distal parent vessels < 2mm. 100% of cases had successful deployment and the stent was repositioned in 10% of cases. A single stent was utilized in 91% of cases. Coils were placed in 48 cases(87.2%) and a microcatheter was jailed in 98% of those cases. Immediate Raymond Roy(RR) Class I occlusion was obtained in 33%, Class II in 22%, Class IIIa in 37% and Class IIIb in 8%. There were no delayed thromboembolic or hemorrhagic complications.

Abstract LB-015 Figure 1

A: Recurrence at the neck of a MCA bifurcation aneurysm following WEB placement B: Y-stent assisted coil embolization with ATLAS in the superior branch and LVIS EVO in the inferior branch. The excellent visualization of the EVO is noted here. C-D: Another MCA bifurcation aneurysm demonstrating the ability to load the stent during deployment to increase neck coverage. The added load is easily visualized

Abstract LB-015 Figure 2

Two cases of stent assisted coil embolization with the LVIS EVO. A-C: Unruptured basilar tip aneurysm highlighting the excellent visibility of the LVIS EVO stent. D-F: Unruptured ACOMM aneurysm demonstrating a jailed catheter in the aneurysm and the excellent visibility of the stent

Conclusion The LVIS EVO is a braided, self-expanding, retrievable stent with enhanced visibility and smaller cell size. The DFT technology results in improved visibility of the stent allowing for more controlled stent positioning and visualization of vessel wall apposition. All cases in our series had complete neck coverage and good wall apposition. There were no thromboembolic or hemorrhagic complications. The LVIS EVO is a good option when some degree of flow diversion is desired or when using a single stent to cover a bifurcation with ‘fluffing’ of the stent to provide better neck coverage.

Disclosures Y. Kayan: None. J. Delgado Almandoz: None. A. Copelan: 2; C; Microvention. 4; C; Piraeus Medical. I. Chaudry: None. C. Matouk: 2; C; Medtronic, Microvention, Stryker, Navigantis, Hybernia, Cerenovus, Silk Road. D. Altschul: None. M. Amir Essibayi: None. O. Goren: None. B. Yim: 2; C; Imperative Care, Q’apel. 3; C; Penumbra. S. Tsappidi: None. Y. Zhang: None. F. Hui: None. E. Samaniego: None. A. Gudino: None. A. Siddiqui: 2; C; Amnis Therapeutics, Apellis Pharmaceuticals, Inc., Asahi Intecc Co Ltd., Boston Scientific, Canon Medical Systems USA, Inc., Cardinal Health 200, LLC, Cerebrotech Medical Systems, Inc., CerebrovaKP,. V. Jaikumar: None. A. Puri: 2; C; Microvention, Route 92, Stryker, Medtronic, Agile, Merit. 4; C; InNeuroCo, NTI, Agile, Galaxy, Perfuze. A. Kuhn: None. J. Singh: None. A. Ringer: None. R. Hanel: None. O. De Toledo: None. G. Dabus: None. M. Gooch: 2; C; Stryker, Rapid Medical. S. Sizdahkhani: None. N. Field: None. A. Custozzo: None. A. Paul: 2; C; Microvention, Penumbra, IRRAS, GT Medical, NICO.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.